Endo, BioDelivery Sciences announces positive results from buprenorphine trial Endo Pharmaceuticals, a subsidiary of Endo International (ENDP) and BioDelivery Sciences (BDSI) announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to placebo. Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea and vomiting.
News For ENDP;BDSI From The Last 14 Days
Check below for free stories on ENDP;BDSI the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.